COVID‐19 patients receiving 160mg of nano‐curcumin daily for 14 days showed a significant decrease (compared to the COVID‐19 patients receiving placebo) in mRNA expression of IL‐6 and IL‐1β in activated peripheral blood mononuclear cells PBMC. Similarly, a significant decrease in IL‐6 and IL‐1β secretion (measured by ELISA) was also observed in serum of COVID‐19 receiving nano‐curcumin compared to placebo. This evidence concerns the gene IL1B and COVID-19.